IntroMedic Valuation

Is A150840 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A150840 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A150840's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A150840's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A150840?

Key metric: As A150840 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A150840. This is calculated by dividing A150840's market cap by their current revenue.
What is A150840's PS Ratio?
PS Ratio	27.9x
Sales	₩8.01b
Market Cap	₩223.67b

A150840 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	27.3x
Enterprise Value/EBITDA	-38.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A150840's PS Ratio compare to its peers?

The above table shows the PS ratio for A150840 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.6x
A039840 DIO	2.1x	17.0%	₩256.2b
A206640 Boditech Med	2.7x	15.9%	₩381.1b
A043150 Value Added Technology	0.8x	8.5%	₩306.0b
A100120 Vieworks	0.9x	9.6%	₩193.7b
A150840 IntroMedic	27.9x	n/a	₩223.7b

Price-To-Sales vs Peers: Insufficient data to calculate A150840's Price-To-Sales Ratio vs. peers for valuation analysis.

Price to Sales Ratio vs Industry

How does A150840's PS Ratio compare vs other companies in the KR Medical Equipment Industry?

2 Companies	Price / Sales	Estimated Growth	Market Cap
A008490 Suheung	0.2x	6.9%	US$110.50m
A083550 KM	0.3x	n/a	US$24.90m

No more companies available in this PS range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A150840 is expensive based on its Price-To-Sales Ratio (27.9x) compared to the KR Medical Equipment industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is A150840's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A150840 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	27.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A150840's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Ray

₩93.3b

RAY Co., Ltd. provides x-ray diagnostic equipment in the dental industry.

A228670

₩6,100.00

-5.7%

-74.0%

Wonbiogen

₩42.7b

Develops and sells medical equipment in South Korea.

A307280

₩1,210.00

-2.1%

-22.9%

Access Bio

₩190.7b

Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.

A950130

₩5,710.00

2.5%

-33.7%